Leif Thuesen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7620303/publications.pdf

Version: 2024-02-01

147 papers	13,556 citations	28274 55 h-index	20961 115 g-index
159 all docs	159 docs citations	159 times ranked	9497 citing authors

#	Article	IF	Citations
1	A Comparison of Coronary Angioplasty with Fibrinolytic Therapy in Acute Myocardial Infarction. New England Journal of Medicine, 2003, 349, 733-742.	27.0	1,191
2	Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet, The, 2010, 375, 727-734.	13.7	885
3	A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet, The, 2009, 373, 897-910.	13.7	755
4	Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. Circulation, 2006, 114, 1955-1961.	1.6	666
5	A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet, The, 2008, 371, 899-907.	13.7	655
6	Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet, The, 2016, 388, 2743-2752.	13.7	620
7	System Delay and Mortality Among Patients With STEMI Treated With Primary Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2010, 304, 763.	7.4	519
8	Direct intramyocardial plasmid vascular endothelial growth factor-A165gene therapy in patients with stable severe angina pectoris. Journal of the American College of Cardiology, 2005, 45, 982-988.	2.8	436
9	2-Year Clinical Outcomes After Implantation of Sirolimus-Eluting, Paclitaxel-Eluting, and Bare-Metal Coronary Stents. Journal of the American College of Cardiology, 2009, 53, 658-664.	2.8	316
10	Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial. Circulation, 2005, 112, 3306-3313.	1.6	296
11	Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet, The, 2020, 395, 191-199.	13.7	280
12	Randomized Comparison of Final Kissing Balloon Dilatation Versus No Final Kissing Balloon Dilatation in Patients With Coronary Bifurcation Lesions Treated With Main Vessel Stenting. Circulation, 2011, 123, 79-86.	1.6	269
13	Routine Thrombectomy in Percutaneous Coronary Intervention for Acute ST-Segmentâ€“Elevation Myocardial Infarction. Circulation, 2006, 114, 40-47.	1.6	242
14	Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions. Journal of the American College of Cardiology, 2007, 50, 463-470.	2.8	229
15	Retrograde Recanalization of Chronic Total Occlusions in Europe. Journal of the American College of Cardiology, 2015, 65, 2388-2400.	2.8	214
16	Heart Failure and Echocardiographic Changes During Long-term Follow-up of Patients With Sick Sinus Syndrome Randomized to Single-Chamber Atrial or Ventricular Pacing. Circulation, 1998, 97, 987-995.	1.6	210
17	Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet, The, 2010, 375, 1090-1099.	13.7	198
18	Five-Year Clinical and Functional Multislice Computed Tomography Angiographic Results After Coronary Implantation of the Fully Resorbable Polymeric Everolimus-Eluting Scaffold in Patients With De Novo Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 999-1009.	2.9	195

#	Article	IF	Citations
19	Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. European Journal of Endocrinology, 1994, 130, 224-228.	3.7	175
20	Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet, The, 2013, 381, 661-669.	13.7	173
21	Randomized Comparison of Coronary Bifurcation Stenting With the Crush Versus the Culotte Technique Using Sirolimus Eluting Stents. Circulation: Cardiovascular Interventions, 2009, 2, 27-34.	3.9	156
22	Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationale. American Heart Journal, 2010, 160, 1042-1048.	2.7	150
23	Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention. Circulation, 2012, 125, 1246-1255.	1.6	149
24	Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. Clinical Epidemiology, 2010, 2, 137.	3.0	147
25	Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. Catheterization and Cardiovascular Interventions, 2007, 70, 515-523.	1.7	137
26	Randomized Comparison of Distal Protection Versus Conventional Treatment in Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2008, 51, 899-905.	2.8	135
27	Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice. JAMA - Journal of the American Medical Association, 2008, 299, 409-16.	7.4	130
28	Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention, 2010, 6, 447-453.	3.2	116
29	Atrioventricular Conduction During Long-Term Follow-Up of Patients With Sick Sinus Syndrome. Circulation, 1998, 98, 1315-1321.	1.6	112
30	Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with deâ€¯novo coronary artery disease: the ABSORB trial. EuroIntervention, 2012, 7, 1060-1061.	3.2	110
31	Short and longâ€term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clinical Endocrinology, 1994, 41, 615-620.	2.4	108
32	The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) Trial. Journal of the American College of Cardiology, 2006, 47, 449-455.	2.8	107
33	Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. Lancet, The, 2015, 385, 1527-1535.	13.7	107
34	Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clinical Endocrinology, 1996, 45, 681-688.	2.4	106
35	Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. European Heart Journal, 2016, 37, 1923-1928.	2.2	103
36	Derivation and Validation of a Chronic Total Coronary Occlusion Intervention Procedural Success Score From the 20,000-Patient EuroCTO Registry. JACC: Cardiovascular Interventions, 2019, 12, 335-342.	2.9	99

#	Article	IF	Citations
37	Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. Lancet, The, 2014, 383, 2047-2056.	13.7	96
38	Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs. 12-72 h. European Heart Journal, 2009, 30, 1322-1330.	2.2	89
39	Health Care System Delay and Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Follow-up of Population-Based Medical Registry Data. Annals of Internal Medicine, 2011, 155, 361.	3.9	81
40	THE CARDIOVASCULAR EFFECTS OF OCTREOTIDE TREATMENT IN ACROMEGALY: AN ECHOCARDIOGRAPHIC STUDY. Clinical Endocrinology, 1989, 30, 619-625.	2.4	78
41	Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients. American Heart Journal, 2017, 190, 54-63.	2.7	78
42	Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: Subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT). American Heart Journal, 2006, 152, 1140-1145.	2.7	76
43	Electromechanical Mapping for Detection of Myocardial Viability in Patients With Ischemic Cardiomyopathy. Circulation, 2001, 103, 1631-1637.	1.6	74
44	Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart, 2013, 99, 98-105.	2.9	72
45	The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. European Heart Journal, 2007, 29, 1259-1266.	2.2	71
46	A Hyperkinetic Heart in Uncomplicated Active Acromegaly. Acta Medica Scandinavica, 1988, 223, 337-343.	0.0	68
47	Outcomes after primary percutaneous coronary intervention in octogenarians and nonagenarians with STâ€segment elevation myocardial infarction: From the Western Denmark heart registry. Catheterization and Cardiovascular Interventions, 2013, 81, 912-919.	1.7	68
48	Potential significance of spontaneous and interventional ST-changes in patients transferred for primary percutaneous coronary intervention: observations from the ST-MONitoring in Acute Myocardial Infarction study (The MONAMI study). European Heart Journal, 2006, 27, 267-275.	2.2	66
49	Drug-Eluting Versus Bare Metal Stents in Patients With ST-Segmentâ€“Elevation Myocardial Infarction. Circulation, 2008, 118, 1155-1162.	1.6	66
50	Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease. Heart, 2013, 99, 655-660.	2.9	62
51	10-Year Clinical Outcome After Randomization to Treatment by Sirolimus-Âor Paclitaxel-Eluting CoronaryÂStents. Journal of the American College of Cardiology, 2017, 69, 616-624.	2.8	60
52	Side branch fractional flow reserve measurements after main vessel stenting: a Nordic-Baltic Bifurcation Study III substudy. EuroIntervention, 2012, 7, 1155-1161.	3.2	59
53	Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis A substudy of the ABSORB clinical trial. EuroIntervention, 2009, 4, 443-448.	3.2	57
54	Safety in simple versus complex stenting of coronary artery bifurcation lesions. The Nordic Bifurcation Study 14-month follow-up results. EuroIntervention, 2008, 4, 229-233.	3.2	56

#	Article	IF	Citations
55	Comparison of the Sirolimus-Eluting Versus Paclitaxel-Eluting Coronary Stent in Patients With Diabetes Mellitus: The Diabetes and Drug-Eluting Stent (DiabeDES) Randomized Angiography Trialâ€â€A list of participating centers and investigators appears in the Appendix.. American Journal of Cardiology, 2009, 103, 345-349.	1.6	55
56	Fiveâ€year longâ€term clinical followâ€up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT FIRST trial. Catheterization and Cardiovascular Interventions, 2010, 75, 997-1003.	1.7	54
57	Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2012, 109, 629-635.	1.6	54
58	Prevalence and Significance of Accelerated Idioventricular Rhythm in Patients With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2009, 104, 1641-1646.	1.6	52
59	System Delay and Timing of Intervention in Acute Myocardial Infarction (from the Danish Acute) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	52
60	Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions. Journal of the American College of Cardiology, 2008, 51, 2011-2016.	2.8	51
61	Influence of pre-infarction angina, collateral flow, and pre-procedural TIMI flow on myocardial salvage index by cardiac magnetic resonance in patients with ST-segment elevation myocardial infarction. European Heart Journal Cardiovascular Imaging, 2012, 13, 433-443.	1.2	48
62	Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention. Circulation, 2020, 141, 2052-2063.	1.6	48
63	Dimensions of Socioeconomic Status and Clinical Outcome After Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2012, 5, 641-648.	3.9	46
64	3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents. JACC: Cardiovascular Interventions, 2012, 5, 812-818.	2.9	43
65	2-Year Patient-Related Versus Stent-Related Outcomes. Journal of the American College of Cardiology, 2012, 60, 1140-1147.	2.8	42
66	Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention, 2010, 5, 898-905.	3.2	42
67	Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With and Without Diabetes Mellitus in Western Denmark. American Journal of Cardiology, 2010, 105, 1513-1519.	1.6	41
68	Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2013, 6, 548-553.	2.9	41
69	Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial. European Heart Journal, 2008, 29, 2733-2741.	2.2	39
70	16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction. European Heart Journal, 2020, 41, 847-854.	2.2	39
71	Electromechanical mapping versus positron emission tomography and single photon emission computed tomography for the detection of myocardial viability in patients with ischemic cardiomyopathy. Journal of the American College of Cardiology, 2003, 41, 843-848.	2.8	38
72	Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 255-264.	2.9	38

#	Article	IF	Citations
73	Increased Rate of Stent Thrombosis and Target Lesion Revascularization After Filter Protection in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2010, 55, 867-871.	2.8	37
74	Primary Percutaneous Coronary Intervention as a National Reperfusion Strategy in Patients With ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2011, 4, 570-576.	3.9	37
75	Culprit only or multivessel percutaneous coronary interventions in patients with ST-segment elevation myocardial infarction and multivessel disease. EuroIntervention, 2012, 8, 456-464.	3.2	37
76	Vascular Response of the Segments Adjacent to the Proximal and Distal Edges of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold: 6-Month and 1-Year Follow-Up Assessment. JACC: Cardiovascular Interventions, 2012, 5, 656-665.	2.9	35
77	Randomised comparison of provisional side branch stenting versus a two-stent strategy for treatment of true coronary bifurcation lesions involving a large side branch: the Nordic-Baltic Bifurcation Study IV. Open Heart, 2020, 7, e000947.	2.3	34
78	Serial optical frequency domain imaging in STEMI patients: the follow-up report of TROFI study. European Heart Journal Cardiovascular Imaging, 2014, 15, 987-995.	1.2	33
79	Clinical Outcome After Primary Percutaneous Coronary Intervention With Drug-Eluting and Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2008, 1, 176-184.	3.9	30
80	Transapical Transcatheter Treatment of a Stenosed Aortic Valve Bioprosthesis Using the Edwards SAPIEN Transcatheter Heart Valve. Annals of Thoracic Surgery, 2009, 87, 1943-1946.	1.3	29
81	Functional significance of recruitable collaterals during temporary coronary occlusion evaluated by 99mTc-sestamibi single-photon emission computerized tomography. Journal of the American College of Cardiology, 2000, 35, 624-632.	2.8	27
82	ST changes before and during primary percutaneous coronary intervention predict final infarct size in patients with ST elevation myocardial infarction. Journal of Electrocardiology, 2009, 42, 64-72.	0.9	27
83	Intravascular ultrasound assessed incomplete stent apposition and stent fracture in stent thrombosis after bare metal versus drug-eluting stent treatment the Nordic Intravascular Ultrasound Study (NIVUS). International Journal of Cardiology, 2013, 168, 1010-1016.	1.7	27
84	Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovascular Disorders, 2014, 14, 100.	1.7	27
85	Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial). EuroIntervention, 2007, 3, 206-212.	3.2	26
86	Influence of a Pressure Gradient Distal to Implanted Bare-Metal Stent on In-Stent Restenosis After Percutaneous Coronary Intervention. Circulation, 2007, 116, 2802-2808.	1.6	25
87	Coronary bifurcation lesions: Present status and future perspectives. International Journal of Cardiology, 2015, 187, 48-57.	1.7	25
88	Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial. Circulation, 2021, 143, 2155-2165.	1.6	25
89	The NUGGET study: NIR ultra gold-gilded equivalency trial. Catheterization and Cardiovascular Interventions, 2004, 62, 18-25.	1.7	21
90	Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. International Journal of Cardiovascular Imaging, 2011, 27, 859-866.	1.5	21

#	Article	IF	Citations
91	Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology. Clinical Epidemiology, 2013, 5, 357.	3.0	21
92	Influence of multivessel disease with or without additional revascularization on mortality in patients with ST-segment elevation myocardial infarction. American Heart Journal, 2015, 170, 70-78.	2.7	21
93	Echocardiographicâ€determined Left Ventricular Wall Characteristics in Insulinâ€dependent Diabetic Patients. Acta Medica Scandinavica, 1988, 224, 343-348.	0.0	20
94	One-year clinical and angiographic results of hybrid coronary revascularization. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 1181-1186.	0.8	20
95	Timing, Causes, and Predictors of Death After Three Years' Follow-Up in the Danish Multicenter Randomized Study of Fibrinolysis Versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) Trial. American Journal of Cardiology, 2009, 104, 210-215.	1.6	18
96	IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimusâ€eluting device during the bioabsorption process. Catheterization and Cardiovascular Interventions, 2010, 75, 914-918.	1.7	18
97	The impact of distal embolization and distal protection on long-term outcome in patients with ST elevation myocardial infarction randomized to primary percutaneous coronary intervention â€“ results from a randomized study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 180-188.	1.0	17
98	The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation. EuroIntervention, 2012, 8, 591-598.	3.2	17
99	Influence of distance from home to invasive centre on invasive treatment after acute coronary syndrome: a nationwide study of 24 910 patients. Heart, 2011, 97, 27-32.	2.9	16
100	Intravascular ultrasound assessment of minimum lumen area and intimal hyperplasia in in-stent restenosis after drug-eluting or bare-metal stent implantation. The Nordic Intravascular Ultrasound Study (NIVUS). Cardiovascular Revascularization Medicine, 2017, 18, 577-582.	0.8	15
101	Effectiveness of â€œDirectâ€•Stenting Without Balloon Predilatation (from the Multilink Tetra) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	14
102	All-cause mortality and major cardiovascular outcomes comparing percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: a meta-analysis of short-term and long-term randomised trials. Open Heart, 2017, 4, e000638.	2.3	14
103	Analysis of 1Âyear virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. International Journal of Cardiovascular Imaging, 2012, 28, 1307-1314.	1.5	13
104	Incidence of definite stent thrombosis or inâ€stent restenosis after drugâ€eluting stent implantation for treatment of coronary inâ€stent restenosis: From Western Denmark heart registry. Catheterization and Cardiovascular Interventions, 2013, 81, 260-265.	1.7	13
105	Similar five-year outcome with paclitaxel- and sirolimus-eluting coronary stents. Scandinavian Cardiovascular Journal, 2014, 48, 148-155.	1.2	11
106	Safety and efficacy of multiple, overlapping polymer-based paclitaxel-eluting stents. EuroIntervention, 2007, 3, 213-221.	3.2	11
107	BENEFICIAL EFFECT OF A LOW-FAT LOW-CALORIE DIET ON MYOCARDIAL ENERGY METABOLISM IN PATIENTS WITH ANGINA PECTORIS. Lancet, The, 1984, 324, 59-62.	13.7	10
108	Distal embolic protection during percutaneous coronary intervention in patients with acute coronary syndromes: The RUBY study. Acute Cardiac Care, 2006, 8, 148-154.	0.2	10

#	Article	IF	Citations
109	Diagnosis and outcome in a prehospital cohort of patients with bundle branch block and suspected acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 176-181.	1.0	9
110	Feasibility and early safety of hybrid coronary revascularisation combining off-pump coronary surgery through J-hemisternotomy with percutaneous coronary intervention. EuroIntervention, 2015, 10, e1-e6.	3.2	9
111	Transatrial Stent-Valve Implantation in a Stenotic Tricuspid Valve Bioprosthesis. Annals of Thoracic Surgery, 2011, 91, e74-e76.	1.3	8
112	Stent Thrombosis is the Primary Cause of ST-Segment Elevation Myocardial Infarction following Coronary Stent Implantation: A Five Year Follow-Up of the SORT OUT II Study. PLoS ONE, 2014, 9, e113399.	2.5	8
113	Chronic total coronary occlusion: treatment results. Scandinavian Cardiovascular Journal, 2017, 51, 197-201.	1.2	8
114	Lower ST-elevation myocardial infarction incidence during COVID-19 epidemic in Northern Europe. Scandinavian Cardiovascular Journal, 2020, 54, 358-360.	1.2	8
115	Ten-year clinical outcome of patients treated with a drug-eluting stent in the proximal left anterior descending artery segment compared with patients stented in other non-left main coronary segments. EuroIntervention, 2018, 14, 764-771.	3.2	8
116	Efecto del armazÃ³n bioabsorbible liberador de everolimus en la aterosclerosis coronaria. Revista Espanola De Cardiologia, 2016, 69, 109-116.	1.2	7
117	In-laboratory femoral sheath removal after heparin reversal by protamine after percutaneous coronary intervention. EuroIntervention, 2005, 1, 66-9.	3.2	7
118	The Abnormal Albuminuria Syndrome in Diabetes. Frontiers in Diabetes, 1993, 12, 86-121.	0.4	6
119	Long Genuine Coronary Artery Lesions Treated with Stiff Tubular or Flexible Coiled Stents. A Randomized Angiographic Follow-up Study. Scandinavian Cardiovascular Journal, 2002, 36, 91-94.	1.2	6
120	Randomized comparison of the coil-design Crossflex and the tubular NIR stent. Catheterization and Cardiovascular Interventions, 2003, 59, 8-12.	1.7	6
121	Impact of the Everolimus-eluting Bioresorbable Scaffold in Coronary Atherosclerosis. Revista Espanola De Cardiologia (English Ed), 2016, 69, 109-116.	0.6	6
122	Clinical Reinfarction according to Infarct Location and Reperfusion Modality in Patients with ST Elevation Myocardial Infarction. Cardiology, 2009, 113, 72-80.	1.4	5
123	In vivo three dimensional optical coherence tomography. A novel imaging modality to visualize the edge vascular response. International Journal of Cardiology, 2013, 164, e35-e37.	1.7	5
124	Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III). American Journal of Cardiology, 2020, 125, 349-353.	1.6	5
125	Catheter-based32P ?-radiation after stent implantation in porcine coronary arteries: Role of source-centering and geographical miss. Catheterization and Cardiovascular Interventions, 2003, 60, 247-257.	1.7	4
126	Diastolic Dysfunction After an Acute Myocardial Infarction in Patients with Antecedent Hypertension. Journal of the American Society of Echocardiography, 2008, 21, 171-177.	2.8	4

#	Article	IF	Citations
127	Stents versus bypass surgery for left main stem stenosis â€“ Authors' reply. Lancet, The, 2017, 389, 1609.	13.7	4
128	Age-Stratified Outcome in Treatment of Left Main Coronary Artery Stenosis: A NOBLE Trial Substudy. Cardiology, 2021, 146, 409-418.	1.4	3
129	Arterial concentration of 99mTc-sestamibi at rest, during peak exercise and after dipyridamole infusion. Clinical Physiology and Functional Imaging, 2004, 24, 394-397.	1.2	2
130	Target vessel revascularization following percutaneous coronary intervention. A 10-year report from the Danish Percutaneous Transluminal Coronary Angioplasty Registry. Scandinavian Cardiovascular Journal, 2005, 39, 30-35.	1.2	2
131	Zotarolimus-eluting versus sirolimus-eluting coronary stent implantation. Interventional Cardiology, 2010, 2, 807-812.	0.0	2
132	Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry. BMC Cardiovascular Disorders, 2012, 12, 84.	1.7	2
133	Myocardial Laser Revascularization ? The End of a New Therapy?. Scandinavian Cardiovascular Journal, 2001, 35, 6-7.	1.2	1
134	Establishing Primary Angioplasty as the Preferred Treatment for Acute Myocardial Infarction. Scandinavian Cardiovascular Journal, 2002, 36, 215-220.	1.2	1
135	Percutaneous Coronary Intervention (PCI) â€“ â€œThe Ugly Duckling?â€• Scandinavian Cardiovascular Journal, 2006, 40, 323-324.	1.2	1
136	Sirolimus-eluting versus bare-metal stent implantation in patients with ostial lesions. International Journal of Cardiology, 2010, 145, 162-163.	1.7	1
137	Review of Registry and Randomised Comparisons of Zotarolimus-eluting and Sirolimus-eluting Coronary Stents in Western Denmark. The European Journal of Cardiovascular Medicine, 2010, 1, .	1.0	0
138	COMMENTARY: Deliver the Drug and Disappear: Is the Bioabsorbable Magnesium Stent Growing Up or Still Shrinking?. Journal of Endovascular Therapy, 2011, 18, 416-417.	1.5	0
139	Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy). BMC Cardiovascular Disorders, 2012, 12, 18.	1.7	0
140	Unmatched Results After Double Kissing Crush Stenting Technique in Distal LeftÂMain Coronary Artery Treatment?. JACC: Cardiovascular Interventions, 2015, 8, 1343-1345.	2.9	0
141	Growth Hormone Replacement and Cardiac Function in the Growth Hormone Deficient Adults. Growth Hormone, 2001, , 29-32.	0.2	0
142	Bifurcations â€“ What Have we Learned from Randomised Trials?. Interventional Cardiology Review, 2012, 7, 49.	1.6	0
143	The Heart in Diabetes in Early and Advanced Nephropathy. , 1988, , 303-311.		0
144	The Heart in Diabetic Nephropathy. , 1992, , 205-217.		0

#	Article	IF	Citations
145	Worsening Clinical Outcome with Increasing Number of So-Called Off-Label or Unapproved Indications for Use of Drug Eluting Stents. World Journal of Cardiovascular Diseases, 2016, 06, 224-234.	0.2	0
146	Abstract from the Bern-Rotterdam registry. EuroIntervention, 2008, 4 Suppl C, C52-4.	3.2	0
147	Randomized comparison of deliverability and in-hospital complications in implantation of BxSonic(R), Express(R), and Flexmaster(R) coronary stents. EuroIntervention, 2005, 1, 273-6.	3.2	0